First Trust Advisors LP Esperion Therapeutics, Inc. Transaction History

First Trust Advisors LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$3.34 - $5.56 $76,055 - $126,606	-22,771 Closed	0 $0
Q4 2021 Feb 08, 2022	BUY	$4.81 - $11.92 $1,664 - $4,124	346 Added 1.54%	22,771 $114,000
Q3 2021 Nov 15, 2021	BUY	$11.34 - $21.37 $138,166 - $260,372	12,184 Added 118.97%	22,425 $270,000
Q2 2021 Aug 16, 2021	BUY	$19.4 - $28.71 $15,209 - $22,508	784 Added 8.29%	10,241 $217,000
Q1 2021 May 14, 2021	SELL	$25.12 - $36.89 $669,046 - $982,528	-26,634 Reduced 73.8%	9,457 $265,000
Q4 2020 Feb 02, 2021	BUY	$24.2 - $35.76 $509,821 - $753,355	21,067 Added 140.22%	36,091 $938,000
Q3 2020 Nov 05, 2020	BUY	$31.18 - $52.71 $333,594 - $563,944	10,699 Added 247.38%	15,024 $558,000
Q2 2020 Jul 22, 2020	BUY	$30.04 - $51.31 $129,923 - $221,915	4,325 New	4,325 $222,000
Q4 2017 Feb 08, 2018	SELL	$43.47 - $67.43 $400,141 - $620,693	-9,205 Closed	0 $0
Q3 2017 Oct 24, 2017	BUY	$43.8 - $52.77 $403,179 - $485,747	9,205	9,205 $461,000

210

129M

1.67M

930K

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $126M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

Stay updated on First Trust Advisors LP with notifications on news.